DNA nanostructure-templated antibody complexes provide insights into the geometric requirements of human complement cascade activation

Abstract

The classical complement pathway is activated by antigen-bound IgG antibodies. Monomeric IgG must oligomerize to activate complement via the hexameric C1q complex, and hexamerizing mutants of IgG appear as promising therapeutic candidates. However, structural data have shown that it is not necessary to bind all six C1q arms to initiate complement, revealing a symmetry mismatch between C1 and the hexameric IgG complex, which has not been adequately explained. Here we use DNA nanotechnology to produce specific nanostructures to template antigens, and thereby control IgG valency. These DNA nano-templated IgG complexes can activate complement on cell-mimetic lipid membranes, which enabled us to determine the effect of IgG valency on complement activation without the requirement to mutate antibodies. We investigated this using biophysical assays together with 3D cryo-electron tomography. Our data revealed that the cleavage of complement component C4 by the C1 complex is proportional to the number of antigens. Increased IgG valency also translated to better terminal pathway activation and membrane attack complex formation. Together, these data provide insights into how nanopatterning antigen-antibody complexes influence the activation of the C1 complex and suggest routes to modulate complement activation by antibody engineering. Furthermore, to our knowledge this is the first time DNA nanotechnology has been used to study the activation of the complement system.